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Abstract
AIM: To estimate the burden of undiagnosed celiac 
disease (CD) in the Mediterranean area in terms of 
morbidity, mortality and health cost. 
METHODS: For statistics regarding the population of 
each country in the Mediterranean area, we accessed 
authoritative international sources (World Bank, World 
Health Organization and United Nations). The prevalence 
of CD was obtained for most countries from published 
reports. An overall prevalence rate of 1% cases/total 
population was finally estimated to represent the fre-
quency of the disease in the area, since none of the 
available confidence intervals of the reported rates signif-
icantly excluded this rate. The distribution of symptoms 
and complications was obtained from reliable reports in 
the same cohort. A standardized mortality rate of 1.8 
was obtained from recent reports. Crude health cost 
was estimated for the years between symptoms and 
diagnosis for adults and children, and was standardized 
for purchasing power parity to account for the different 
economic profiles amongst Mediterranean countries.
RESULTS: In the next 10 years, the Mediterranean 
area will have about half a billion inhabitants, of which 
120 million will be children. The projected number 
of CD diagnoses in 2020 is 5 million cases (1 million 
celiac children), with a relative increase of 11% com-
pared to 2010. Based on the 2010 rate, there will be 
about 550 000 symptomatic adults and about 240 000 
sick children: 85% of the symptomatic patients will 
suffer from gastrointestinal complaints, 40% are likely 
to have anemia, 30% will likely have osteopenia, 20% 
of children will have short stature, and 10% will have 
abnormal liver enzymes. The estimated standardized 
medical costs for symptomatic celiac patients during 
the delay between symptom onset and diagnosis (mean 
6 years for adults, 2 years for children) will be about €4 
billion (€387 million for children) over the next 10 years. 
A delay in diagnosis is expected to increase mortal-
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ity: about 600 000 celiac patients will die in the next 
10 years, with an excess of 44.4% vs  age- and sex-
matched controls. 
CONCLUSION: In the near future, the burden of CD 
will increase tremendously. Few Mediterranean coun-
tries are able to face this expanding epidemic alone. 
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Recent epidemiological studies show that the prevalence 
of  celiac disease (CD) is underestimated not only in Eu-
rope, but also among the populations of  Mediterranean 
regions such as the Middle East and North Africa[1-3], 
where its prevalence is similar to that recently observed 
in Western countries[4]. Indeed, in these two regions, a 
very high prevalence of  CD has recently been reported 
both in the general population and in at-risk groups[2]. 
These high frequencies are associated with the wide-
spread consumption of  wheat and barley[1,5] and the high 
frequency of  the DR3-DQ2 CD-predisposing haplo-
types in these populations[6,7]. But these factors alone do 
not satisfactorily account for the spread of  the CD epi-
demic in recent years[8,9]. The prevalence of  CD among 
the general population varies from 0.14% to 1.17%[10-20]: 
1%-1.3% in Turkey[10-12], 0.6%-0.96% in Iran[13,14], 0.5% 
in Egypt[15], 0.6% in Tunisia and Israel[16-19], and < 0.5% 
in Jordan, Lebanon and Kuwait[5,20]. Among high-risk 
groups [including patients with a positive family history, 
insulin-dependent diabetes mellitus (IDDM), thyroiditis] 
the prevalence of  CD ranges from 2.4% to 44%, as-
sessed by serological markers and biopsy[21-24].
Egypt, and indeed all North African countries, were 
significant producers of  wheat, and largely used barley 
for beer brewing; they were considered the “granary”
of  Romans for over 4 centuries. Bread, mostly made of  
wheat flour and called “the survival” in some local lan-
guages[1], has been a staple food for thousands of  years. 
Similarly, the widespread use of  couscous [from grossly 
milled durum wheat (Triticum durum)] dates back over 
2000 years. But the use of  wheat and other gluten-con-
taining cereals is also increasing in the countries where it 
has been a staple for centuries[25,26].
The diffusion of  pasta across all the Mediterranean 
countries is relatively recent and stems from the indus-
trial development of  grain processing. Unfortunately, 
a side effect of  this positive dispersal may be the enor-
mous increase in gluten intolerance, which is at a truly 
epidemic level. CD is now a widespread public health 
problem that also involves the populations of  develop-
ing countries, as well as China and India[27,28].  However, 
this epidemic is not fully recognized since a sizeable 
number of  cases are neither diagnosed nor cared for. In 
many Mediterranean countries, few cases are diagnosed 
because of  the low level of  awareness, knowledge and 
skill to deal with the problem, the lack of  diagnostic re-
sources and the attribution of  CD symptoms to other, 
similar, illnesses[5,20]. The low awareness of  CD often 
leads to a delay in diagnosis, which contributes to an 
excess of  medical costs (CD includes growth failure, in-
fant malnutrition, gastrointestinal diseases, anemia and 
more than 20 associated symptoms and conditions) and 
mortality. 
All partners taking part in this study agreed that, to 
date, the best available estimation of  CD-associated medi-
cal cost was that reported by Long et al[29], and supported 
by Hershcovici et al[31]. The annual medical cost in the year 
preceding the diagnosis of  CD, excluding diagnostic costs, 
was estimated to be $5023/patient, $1764 more than the 
cost of  the same patients in the year after diagnosis[29]. In 
the four years preceding the diagnosis of  symptomatic 
CD, the direct medical cost was estimated to be $11 037/
patient. For a symptom- and age-matched control in-
dividual, not affected by CD, the cost after 4 years was 
estimated at $7073, with a difference of  $3964 (about 
$1000/patient per year). This difference is due to in-
creased in-patients admissions, out-patient cost, labora-
tory tests, radiology, and office visits[29]. The diagnosis of  
CD resulted in a 30% reduction in direct medical expen-
diture. A similar 30% reduction in direct medical costs 
after diagnosis of  CD was reported by Green et al[30]; the 
mean medical expenditure decreased from $8502 per 
capita to $7133 for the 2 years after diagnosis of  CD. 
The CD epidemic is the largest epidemic of  food-
induced permanent disease in the Euro-Mediterranean 
region. Very few countries of  this region are able to 
face this expanding problem. The aim of  this study was 
to estimate what the burden of  CD will be in the near 
future, and how the CD epidemic will affect morbidity, 
mortality and health costs. We aim to provide stakehold-
ers with a reliable prediction of  the incoming picture of  
CD in the Mediterranean area, and so enable them to 
take action to face this epidemic.
MATERIALS AND METHODS
Population statistics
For statistics regarding each country in the Mediterra-
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nean area, we accessed authoritative international sources 
(World Bank, World Health Organization and United 
Nations). Population size, median age, number of  chil-
dren (0-14 years), population growth rate, birth rate, 
death rate, infant mortality rate and literacy were re-
trieved and validated across multiple sources. The pro-
jected population from 2010 to 2020 was computed by 
adopting the 2008 growth rate as a constant over the fol-
lowing decade because the predicted rate of  change of  
the growth rate would have not significantly affected our 
estimate. The number of  children was incremented year-
ly by the birth rate and corrected for the infant mortality 
rate although mortality from 1 to 14 years is minimal in 
all the countries included in this evaluation. 
Celiac disease
The prevalence of  CD among the populations of  Medi-
terranean countries, such as the Middle East and North 
Africa[1-3], is similar to that recently observed in Western 
countries[4]. The prevalence of  CD among the general 
population varies from 0.14% to 1.17%[10-20]: 1%-1.3% in 
Turkey[10-12], 0.6%-0.96% in Iran[13,14], 0.5% in Egypt[15], 
0.6% in Tunisia and Israel[16-19], and < 0.5% in Jordan, 
Lebanon and Kuwait[5,20]. An overall prevalence rate of  
1% cases/total population was finally estimated to bet-
ter represent the frequency of  the disease in the area, 
since none of  the available confidence intervals of  the 
reported rates significantly excluded this 1% rate. The 
rate of  symptomatic vs asymptomatic patients was ob-
tained from several reliable reports from the area[3,9,10,17]. 
In summary, 85% of  symptomatic patients are likely to 
suffer from gastrointestinal symptoms, which include 
diarrhea, abdominal pain, vomiting, irritable bowel, and 
gastritis[5,13,20,32-37]. Among the non-gastrointestinal com-
plaints, the available estimates suggest 20% of  children 
are affected by short stature[5,20,33-35,37], 40% of  all cases are 
affected by anemia[5,20,32,36,37], 30% are afflicted by osteope-
nia[32,33,35,37], and 10% by abnormal liver enzymes[37,38].
Mortality has been reported in excess of  1.8 compared 
to age- and sex-matched controls[31,39,40]. The risk of  can-
cer in undiagnosed adults is significantly increased and the 
mortality is almost doubled in the total cohort of  affected 
persons compared with the general population[41,44].
Crude medical costs
Crude health costs were estimated for the years between 
symptoms and diagnosis only for symptomatic adults and 
children, and were standardized for purchasing power 
parity (PPP) to account for the different economic pro-
file among Mediterranean countries. Since gross national 
product is different across countries, the PPP is based on 
the law of  one price; in the absence of  transaction costs, 
identical goods will have the same price in different mar-
kets. The PPP equalizes the purchasing power of  differ-
ent currencies for a given basket of  goods, thereby pro-
viding a standardized estimate of  cost across countries.
We assume that the cohort of  CD without symptoms 
does not increase the average medical cost compared 
to non CD individuals (but this should also be revised, 
since a significant number of  patients identified by 
screening had a posteriori clinical symptoms). Therefore, 
medical costs are estimated only for 1:7 adults and 1:5 
children with CD symptoms. 
For each individual adult we assigned (on the basis of  
the reports cited and the clinical experience of  the study 
partners), a minimal period of  6 years of  delay between 
symptom onset and diagnosis of  the disease[45,46], while 
this delay was two years for each assigned child with 
CD[9,20]. During that period an adult with CD required, 
in excess of  age- and sex-matched controls, at least: 2 in-
patient admissions, 1 out-patient admission, 3 primary 
medical consultations, 2 specialized consultations, and 4 
laboratory tests. Similarly, children needed at least: 1 in-
patient admission and 1 out-patient admission, 3 medical 
consultations, 1 specialized consultation and 2 laboratory 
tests (Table 1).
Estimated medical costs 
The costs of  health services were estimated based on 
the 2007 costs of  the Italian National Health Service 
(NHS) which is similar to that of  several European 
countries. We summed the total costs of  the medical 
services required for each child or adult patient to obtain 
a standardized cost/per patient before the diagnosis of  
CD was made (Table 1). In this way, we obtained an esti-
mation of  the financial load (only for medical expenses) 
of  symptomatic patients. The estimated cost according 
to the Italian NHS was then standardized for each coun-
try according to its PPP index. The total load of  medical 
expenses for each country was calculated by multiplying 
the individual cost by the number of  symptomatic pa-
tients estimated (adults and children).
Summary of reference data
(1) CD prevalence �� 1%; incidence: new cases/year       
estimated at 1% of  the live births, corrected for infant 
mortality rate; (2) symptomatic adults: 1 of every 7 cases,         
children 1:5 cases; (3) mortality of the total CD cohort:        
standardized mortality rate 1.8 compared to age- and 
sex-matched population; (4) delay between symptoms     
and diagnosis: adults 6 years, children 2 years; (5) as-  
sociated conditions: 10%-15% of  the total cohort - au-
toimmune disorders 30% (Turkey 1.9%, Iran 33%) and 
IDDM 10% (6.7%-18.5%); (6) complications: 16% of     
symptomatic CD patients; and (7) non gastrointestinal     
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n Adult cost (€) n Child cost (€)
  In-patient admission 2         9818 1          2254
  Out-patient admission 1           879 1            586
  Medical consultations 3           100 3            150
  Specialist consultations 2           150 1              50
  Lab test 4           446 2            297
  Total per patient      11 393          3337
Table 1  Excess need of health resources before the diagnosis of 
celiac disease
Greco L et al.  Celiac burden
symptoms: short stature 20% (only children), anemia 
40% (20%-80%), osteopenia 30% (30%-50%), abnormal 
liver function 10% (Turkey 38%, Iran 25%) 
RESULTS 
Table 2 shows the population growth, number of  chil-
dren aged 0-14 years and the predicted figures for the 
year 2020, calculated based on a constant growth rate. 
The Mediterranean area will have about half  a billion 
individuals by the year 2020, more than 100 million of  
which will be children aged 0-14 years. This estimate is 
likely to be in the low range, since some countries with a 
large population are likely to grow at a higher rate than 
this estimate before the year 2010.
Table 3 shows the prevalence of  CD in each country in 
2010 and the predicted prevalence in 2020. Within 10 years, 
the Mediterranean area will have to face more than 5 
million cases of  CD, one million of  which will be in chil-
dren. The large majority will not have clear symptoms 
and their diagnosis and care will be significantly delayed. 
Among the adult CD population, about 550 000 will 
present symptoms, while only 240 000 out of  the 1 mil-
lion estimated celiac children will be symptomatic. Table 
4 shows the estimated number of  clinical complaints as-
sociated with the CD epidemic. It is likely that more than 
48 000 children will be affected by growth failure, there 
will be 317 000 cases of  anemia and 238 000 individu-
als will be afflicted with osteopenia. Table 5 shows the 
estimated financial burden of  the CD epidemic. There 
is no scope for a detailed calculation of  costs, which will 
be related more to the availability of  and access to medi-
cal services than to the actual cost of  the service, but 
these figures help to understand the financial burden of  
the undiagnosed disease. European countries may not 
be impressed by these estimates but, for several other 
Mediterranean countries, these predicted costs might be a 
consistent load to the gross national product. More than 
€4 billion is a prudent estimate; only crude medical costs 
are included, not individual or social cost.
Table 6 shows the estimated number of  deaths in the 
celiac disease cohort and the excess of  deaths compared 
to age- and sex-matched controls. At the present rate, 
there will be more than 250 000 CD-related deaths in the 
Mediterranean area in 2020.
DISCUSSION
Celiac disease is a very common chronic disease that 
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Population Children 0-14 Median age (yr) Population growth rate (%) Children 0-14 in 10 yr Total population in 10 yr
  Albania        3 619 778             853 883         29.9                       0.5              901 667               3 822 345
  Algeria      33 769 669          8 878 665         26.6                       1.2           9 999 566             38 032 972
  Bosnia        4 590 310             673 770         39.8                       0.3              696 962               4 748 317
  Cyprus           792 604             154 445         35.5                       1.7              182 623                  937 214
  Croatia        4 491 543             708 683         41                      -0.1              705 006               4 468 242
  Egypt      81 713 517        25 983 672         24.8                       2         31 776 575             99 931 053
  France      64 057 790        11 894 698         39.4                       0.5         12 564 088             67 662 729
  Greece      10 722 816          1 531 606         41.8                       0.1           1 551 169             10 859 777
  Israel        7 112 359          1 989 312         29.1                       1.7           2 347 869               8 394 303
  Italy      58 126 212          7 870 226         43.3                       0           7 833 314             57 853 596
  Lebanon        3 971 941          1 032 888         29.3                       1.1           1 153 096               4 434 197
  Libya        6 173 579          2 048 548         23.9                       2.2           2 539 599               7 653 427
  Malta           403 532               66 112         39.5                       0.4                68 805                  419 967
  Morocco      34 343 219        10 473 478         25                       1.1         11 683 138               8 309 775
  Syria      19 747 586          7 146 569         21.7                       2           8 716 754             24 086 361
  Slovenia        2 007 711             273 464         41.5                       0              273 655               2 009 117
  Spain      40 525 002          5 864 419         41.1                       0.1           5 906 780             40 817 729
  Tunisia      10 383 577          2 413 484         29.2                       1           2 660 713             11 447 236
  Turkey      71 892 807        17 545 890         27.7                       1.3         19 965 025             81 805 009
  Mediter    458 445 552      107 403 812         33.2                       0.9       121 526 405           507 693 365
Table 2  Populations now and after 10 years
Estimated 
celiacs today 
Estimated 
celiac children 
today at 1%
Projected 
prevalence of 
CD in next 
10 yr
Projected 
celiac children 
in next 10 yr
  Albania       36 198          8539        38 223            9017
  Algeria     337 697       88 787      380 330         99 996
  Bosnia       45 903          6738        47 483            6970
  Cyprus          7926          1544           9372            1826
  Croatia       44 915          7087        44 682            7050
  Egypt     817 135     259 837      999 311       317 766
  France     640 578     118 947      676 627       125 641
  Greece     107 228       15 316      108 598         15 512
  Israel       71 124       19 893        83 943         23 479
  Italy     581 262       78 702      578 536         78 333
  Lebanon       39 719       10 329        44 342         11 531
  Libya       61 736       20 485        76 534         25 396
  Malta          4035            661           4200              688
  Morocco     343 432     104 735      383 098       116 831
  Syria     197 476       71 466      240 864         87 168
  Slovenia       20 077          2735        20 091            2737
  Spain     405 250       58 644      408 177         59 068
  Tunisia     103 836       24 135      114 472         26 607
  Turkey     718 928     175 459      818 050       199 650
  Mediter  4 584 456  1 074 038   5 076 934    1 215 264
Table 3  Prevalence of celiac disease in the next 10 years1
1Population prevalence estimated at minimum rate of 1%. CD: Celiac disease.
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affects adults and children in all wheat-consuming coun-
tries. It has also recently been reported in countries 
where its prevalence was previously unknown, such as 
China[27]. For more than two decades, we have been dis-
cussing the difference in the prevalence of  CD among 
countries in Europe, North America and South America, 
and the conclusion is that there is no country where 
CD prevalence is significantly different from the overall 
prevalence of  about 1%. Interestingly, the prevalence, 
at a global level, is not related either to the amount of  
wheat consumed by each country or to the prevalence 
of  the human leukocyte antigen (HLA) DR3-DQ2 and 
DR4-DQ8 haplotype worldwide[47]. 
An excess prevalence of  CD has been reported in an 
isolated population in North Africa and in a large popu-
lation in Sweden, but again it is plausible that this excess 
prevalence reflects a bias related to the cohort rather 
than a true excess. The prevalence of  CD is increasing 
worldwide, including in Europe[4], China[27] and India[28]. 
The only region where it has not yet been described is 
Central Africa, and this may be explained by the absence 
in this region of  HLA predisposing haplotypes, and of  
polymorphisms of  the major non-HLA genes, namely 
SH2B3, IL12A, SCHIP, IL18RAP, and IL1RL1, among 
others[47,48]. Recently, Barada et al[2] from Lebanon pro-
duced a comprehensive report of  the situation in the 
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Symptomatic adults 
next 10 yr 1:7
Symptomatic children 
next 10 yr 1:5
Gastrointestinal 
symptoms Anaemia Osteopenia Abnormal liver Children with short stature 
  Albania                   4172                   1803           5079         2390            1793              598                         361
  Algeria                40 048                19 999        51 040      24 019         18 014            6005                       4000
  Bosnia                   5788                   1394           6104         2873            2154              718                         279
  Cyprus                   1078                     365           1227           577              433              144                           73
  Croatia                   5376                   1410           5768         2714            2036              679                         282
  Egypt                97 364                63 553      136 779      64 367         48 275         16 092                    12 711
  France                78 712                25 128        88 264      41 536         31 152         10 384                       5026
  Greece                13 298                   3102        13 940         6560            4920            1640                         620
  Israel                   8638                   4696        11 333         5333            4000            1333                         939
  Italy                71 458                15 667        74 056      34 850         26 137            8712                       3133
  Lebanon                   4687                   2306           5944         2797            2098              699                         461
  Libya                   7305                   5079        10 527         4954            3715            1238                       1016
  Malta                     502                     138             543           256              192                64                           28
  Morocco                38 038                23 366        52 194      24 562         18 421            6140                       4673
  Syria                21 957                17 434        33 482      15 756         11 817            3939                       3487
  Slovenia                   2479                     547           2573         1211              908              303                         109
  Spain                49 873                11 814        52 433      24 675         18 506            6169                       2363
  Tunisia                12 552                   5321        15 193         7149            5362            1787                       1064
  Turkey                88 343                39 930      109 032      51 309         38 482         12 827                       7986
  Mediter              551 667              243 053      675 512    317 888       238 416         79 472                    48 611
Table 4  Symptoms and diseases associated with symptomatic cases
Purchasing power 
parity
Standardized cost 
for an adult in 6 yr 
of delay, €
Standardized cost 
for a child in 2 yr 
of delay, €
Total cost for adults in 
the next 10 yr, €
Total cost for children 
in the next 10 yr, €
Total cost of 
symptomatic in the next 
10 yr, €
  Albania               7.164               2804                821            11 698 575           1 481 020                13 179 595
  Algeria               6.869               2688                787          107 662 164         15 748 296              123 410 460
  Bosnia               7.361               2881                844            16 673 654           1 176 265                17 849 919
  Cyprus             17.7               6928              2029              7 468 819              741 246                  8 210 065
  Croatia             28.54            11 171              3272            60 057 866           4 613 886                64 671 751
  Egypt               6.123               2396                702          233 320 214         44 609 799              277 930 013
  France             33.68            13 181              3861       1 037 513 563         97 017 277           1 134 530 840
  Greece             29.88            11 695              3426          155 520 664         10 627 416              166 148 080
  Israel             28.39            11 112              3255            95 985 202         15 284 247              111 269 450
  Italy             29.11            11 393              3337          814 080 086         52 279 538              866 359 625
  Lebanon             14.23               5568              1631            26 097 336           3 761 033                29 858 369
  Libya             14.33               5608              1643            40 966 178           8 342 757                49 308 935
  Malta             23.58               9230              2704              4 630 407              372 044                  5 002 450
  Morocco               4.604               1802                528            68 540 194         12 332 575                80 872 769
  Syria               4.7               1839                539            40 388 186           9 393 156                49 781 342
  Slovenia             29.69            11 619              3403            28 807 411           1 862 767                30 670 178
  Spain             33.7            13 189              3863          657 786 976         45 639 366              703 426 342
  Tunisia               8.254               3230                946            40 548 541           5 035 255                45 583 796
  Turkey             12.48               4883              1430          431 358 582         57 108 945              488 467 527
  Mediter             17.92               7012              2054       3 879 104 619       387 426 887           4 266 531 506
Table 5  Excess cost of undiagnosed symptomatic celiac patients
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countries that face the Mediterranean Sea, thereby in-
creasing the awareness of  CD in the area. 
The EUROMED program supports several health-
promoting activities across the Mediterranean, such as 
the surveillance of  infectious diseases program and the 
Program for Transplants and Oncology EuroMed (Can- 
cer Registries Network, Cancer screening and early diag-    
nosis program, Mediterranean Transplant Network). Italy 
has requested that the CD epidemic be included in these 
programs (www.eeas.europa.eu/euromed/index_en.
htm). The first step in facing this epidemic is to estimate 
the burden of  CD in the area. Here we provide a reliable 
and simple picture of  the present situation and a predic-
tion of  the development of  the CD epidemic in the next 
10 years, up to 2021.
The prediction obtained by simple straightforward 
calculations is impressive. Mediterranean countries will 
have to be prepared to deal with a considerable number 
of  CD patients in the near future. There will be more 
than 5 million cases, one million of  which will be chil-
dren. But, more than the overall figures, each country 
will be especially concerned about the national figures. 
Our estimates are conservative figures, since we estimat-
ed a constant population growth over the next ten years, 
whereas the faster growing countries may have a more 
rapid growth rate than slower growing countries. Data 
on symptoms and common clinical problems are avail-
able only for symptomatic individuals, while a consider-
able percentage of  so-called “asymptomatic” subjects 
notoriously report significant complaints a posteriori[49]. A 
limitation of  this study is related to the uncertainties in-
herent in any prediction given the wide confidence inter-
vals of  rates. However, the starting 1% prevalence rate is 
not only very robust, because of  innumerable replications, 
but it also probably underestimates rather than overesti-
mates the problem[4,28,50]. The rate of  symptomatic versus 
asymptomatic individuals is also fairly conservative. 
The financial burden estimate is not aimed to acquire 
more precision; we provide a gross figure for the spec-
trum of  resources needed in each country for the ser-
vices required by symptomatic patients. The priority issue 
is the availability of  services; in many African countries, 
services are mostly only available in large cities and spe-
cialized health institutions. In the rural areas, the availabil-
ity of  services can be far less than that required. Hence, 
the cost of  these services should, sadly, be subtracted 
from the total financial burden. This impending cohort 
of  CD patients does require, and moreover will require, 
access to health services as inpatients or outpatients, for 
medical consultations, laboratory tests and, after diagno-
sis, financial support for a lifelong gluten-free diet. There 
is universal concern and many countries demand the ex-
pertise and support for dissemination of  know how and 
capacity building for the management of  CD.
The EuroMed - MEDICEL project (www.medicel.
unina.it) offers a platform to analyze the problem and 
develop strategies, but active national plans are required 
to face the burgeoning epidemic, and the heavy burden 
that it will place on the health and the finances of  the 
population.
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Background
The incidence of celiac disease (CD) (i.e., permanent gluten intolerance), is 
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Projected prevalence of CD 
in the next 10 yr
Death rate, 
deaths/1000 individuals
Population expected deaths 
(next 10 yr)
Celiac deaths 
in next 10 yr
Excess celiac deaths 
in next 10 yr
  Albania                    38 223                     5.1                         193 793                3488                     1550
  Algeria                  380 330                     4.6                      1 764 730             31 765                  14 118
  Bosnia                    47 483                     8.6                         409 780                7376                     3278
  Cyprus                       9372                     6.4                           59 982                1080                       480
  Croatia                    44 682                   11.8                         525 018                9450                     4200
  Egypt                  999 311                     4.9                      4 876 635             87 779                  39 013
  France                  676 627                     8.6                      5 791 930           104 255                  46 335
  Greece                  108 598                   10.5                      1 141 363             20 545                     9131
  Israel                    83 943                     5.4                         455 811                8205                     3646
  Italy                  578 536                   10.7                      6 201 905           111 634                  49 615
  Lebanon                    44 342                     6                         267 382                4813                     2139
  Libya                    76 534                     3.4                         260 982                4698                     2088
  Malta                       4200                     8.4                           35 193                  633                       282
  Morocco                  383 098                     4.7                      1 815 883             32 686                  14 527
  Syria                  240 864                     3.7                         896 013             16 128                     7168
  Slovenia                    20 091                     9.2                         184 839                3327                     1479
  Spain                  408 177                   10                      4 077 691             73 398                  32 622
  Tunisia                  114 472                     5.2                         595 256             10 715                     4762
  Turkey                  818 050                     6                      4 908 301             88 349                  39 266
  Mediter               5 076 934                     7                    34 462 486           620 325                275 700
Table 6  Excess mortality in undiagnosed cases2
2Undiagnosed celiac patients have 1.8 standard mortality rate[39] . CD: Celiac disease.
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increasing in all countries in which there is awareness of this intolerance. In 
all Western countries, including the United States and South America, the 
observed prevalence of the disease went from 1:1000 individuals to more than 
1:100 individuals in two decades. However, large series of cases have recently 
been reported from “new” countries like India, China, North Africa and the 
Middle East. Celiac disease is expanding over and above any predicted trend, 
and has taken on the semblance of a real epidemic.
Research frontiers
This expanding “epidemic” raises a series of unanswered research questions 
related to the following hot topics: (1) the weight of environmental factors in the         
increase of CD�� ���� ��e �ene�ic �ro���e associa�e�� �i�� �re��is�osi�ion �o CD�� ����           
population differences in terms of genetic and environmental factors�� and (�)   
the development of “sensitivity” to gluten.
Innovations and breakthroughs
In next 10 years, the Mediterranean area will have about half a billion inhabit-
ants, 120 million of whom will be children. The projected number of CD cases 
in 2020 will be 5 million cases (1 million celiac children), with a relative increase 
of 11% compared to 2010. At a 2010 constant rate, there will be about 550 000 
symptomatic adults and 2�0 000 sick children: 85% of patients will suffer from 
�as�roin�es�ina� com��ain�s, 40% are �ike�y �o �ave anemia, �0% �i�� be afflic�e�� 
with osteopenia, 20% of children will have short stature and 10% will have ab-
normal liver enzymes. The estimated standardized medical costs for symptom-
atic celiac disease during the years of delay between onset of symptoms and 
��ia�nosis �mean: 6 years for a��u��s, � years for c�i���ren�� �i�� be abou� €4 bi��ion 
�€�87 mi��ion for ��e c�i���ren�� over ��e nex� 10 years. A ��e�ay in ��ia�nosis is ex-
pected to increase mortality�� about 600 000 deaths will occur among individuals 
affected by CD in the next 10 years, with an excess of ��.�% compared to age- 
and sex-matched controls. 
Applications 
The data produced in this study provide a picture of the cohort of patients af-
fected by CD that will develop over the next 10 years in each country of the 
Mediterranean Basin. Stakeholders and health professionals in each country 
no� �ave ��e ���ures �i�� ��ic� i� is �ossib�e �o base a��equa�e ��ans �o face 
��is e�i��emic. T�e ��ia�nos�ic �ro�oco� mus� be sim��i��e�� an�� ma��e avai�ab�e 
not only in specialized centers, usually in large cities, but it should be especially 
important in rural districts.
Terminology 
CD: Celiac disease is a permanent intolerance to gluten based on a genetic 
predisposition�� �rojected prevalence: The number of celiac cases that are          
expected to be present over the next 10 years�� Excess mortality: Undiagnosed    
celiac cases have twice the risk of death compared to age- and sex-matched 
controls. If the expected cases are not diagnosed, there will be more than 
200 000 excess deaths in the Mediterranean area�� �rowth failure: 20% of chil-     
dren (about 50 000) with undiagnosed CD are affected by weight loss and short 
stature, due to a growth failure.
Peer review
The paper is well written and deals with an important problem people are con-
tinuously facing.
REFERENCES
1 Cataldo F, Montalto G. Celiac disease in the developing 
countries: a new and challenging public health problem. 
World J Gastroenterol 2007; 13: 2153-2159
2 Barada K, Bitar A, Mokadem MA, Hashash JG, Green P. Ce-
liac disease in Middle Eastern and North African countries: 
a new burden? World J Gastroenterol 2010; 16: 1449-1457  
3 Rostami K, Malekzadeh R, Shahbazkhani B, Akbari MR, 
Catassi C. Coeliac disease in Middle Eastern countries: a 
challenge for the evolutionary history of this complex disor-
der? Dig Liver Dis 2004; 36: 694-697  
4 Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, 
McMillan S, Murray L, Metzger MH, Gasparin M, Bravi E, 
Mäki M. The prevalence of celiac disease in Europe: results 
of a centralized, international mass screening project. Ann 
Med 2010; 42: 587-595
5 Rawashdeh MO, Khalil B, Raweily E. Celiac disease in Ar-
abs. J Pediatr Gastroenterol Nutr 1996; 23: 415-418 
6 Bouguerra F, Babron MC, Eliaou JF, Debbabi A, Clot J, 
Khaldi F, Greco L, Clerget-Darpoux F. Synergistic effect of 
two HLA heterodimers in the susceptibility to celiac disease 
in Tunisia. Genet Epidemiol 1997; 14: 413-422 
7 Catassi C, Rätsch IM, Gandolfi L, Pratesi R, Fabiani E, El 
Asmar R, Frijia M, Bearzi I, Vizzoni L. Why is coeliac dis-
ease endemic in the people of the Sahara? Lancet 1999; 354: 
647-648
8 Lohi S, Mustalahti K, Kaukinen K, Laurila K, Collin P, Ris-
sanen H, Lohi O, Bravi E, Gasparin M, Reunanen A, Mäki M. 
Increasing prevalence of coeliac disease over time. Aliment 
Pharmacol Ther 2007; 26: 1217-1225
9 Roma E, Panayiotou J, Karantana H, Constantinidou C, 
Siakavellas SI, Krini M, Syriopoulou VP, Bamias G. Chang-
ing pattern in the clinical presentation of pediatric celiac 
disease: a 30-year study. Digestion 2009; 80: 185-191
10 Gursoy S, Guven K, Simsek T, Yurci A, Torun E, Koc N, 
Patiroglu TE, Ozbakir O, Yucesoy M. The prevalence of 
unrecognized adult celiac disease in Central Anatolia. J Clin 
Gastroenterol 2005; 39: 508-511
11 Tatar G, Elsurer R, Simsek H, Balaban YH, Hascelik G, 
Ozcebe OI, Buyukasik Y, Sokmensuer C. Screening of tissue 
transglutaminase antibody in healthy blood donors for ce-
liac disease screening in the Turkish population. Dig Dis Sci 
2004; 49: 1479-1484
12 Ertekin V, Selimoğlu MA, Kardaş F, Aktaş E. Prevalence of 
celiac disease in Turkish children. J Clin Gastroenterol 2005; 
39: 689-691
13 Akbari MR, Mohammadkhani A, Fakheri H, Javad Zahedi 
M, Shahbazkhani B, Nouraie M, Sotoudeh M, Shakeri R, 
Malekzadeh R. Screening of the adult population in Iran for 
coeliac disease: comparison of the tissue-transglutaminase 
antibody and anti-endomysial antibody tests. Eur J Gastro-
enterol Hepatol 2006; 18: 1181-1186
14 Shahbazkhani B, Malekzadeh R, Sotoudeh M, Moghadam 
KF, Farhadi M, Ansari R, Elahyfar A, Rostami K. High prev-
alence of coeliac disease in apparently healthy Iranian blood 
donors. Eur J Gastroenterol Hepatol 2003; 15: 475-478 
15 Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. 
Prevalence of celiac disease in Egyptian children disputes 
the east-west agriculture-dependent spread of the disease. J 
Pediatr Gastroenterol Nutr 2008; 47: 136-140 
16 Mankaï A, Landolsi H, Chahed A, Gueddah L, Limem M, 
Ben Abdessalem M, Yacoub-Jemni S, Ghannem H, Jeddi M, 
Ghedira I. Celiac disease in Tunisia: serological screening in 
healthy blood donors. Pathol Biol (Paris) 2006; 54: 10-13  
17 Ben Hariz M, Kallel-Sellami M, Kallel L, Lahmer A, Halioui 
S, Bouraoui S, Laater A, Sliti A, Mahjoub A, Zouari B, Makni 
S, Maherzi A. Prevalence of celiac disease in Tunisia: mass-
screening study in schoolchildren. Eur J Gastroenterol Hepatol 
2007; 19: 687-694
18 Bdioui F, Sakly N, Hassine M, Saffar H. Prevalence of celiac 
disease in Tunisian blood donors. Gastroenterol Clin Biol 
2006; 30: 33-36
19 Shamir R, Lerner A, Shinar E, Lahat N, Sobel E, Bar-or R, 
Kerner H, Eliakim R. The use of a single serological marker 
underestimates the prevalence of celiac disease in Israel: a 
study of blood donors. Am J Gastroenterol 2002; 97: 2589-2594 
20 Khuffash FA, Barakat MH, Shaltout AA, Farwana SS, Ad-
nani MS, Tungekar MF. Coeliac disease among children in 
Kuwait: difficulties in diagnosis and management. Gut 1987; 
28: 1595-1599
21 Bouguerra R, Ben Salem L, Chaâbouni H, Laadhar L, Es-
sais O, Zitouni M, Haouet S, Ben Slama C, Ben Ammar A, 
Zouari B, Makni S. Celiac disease in adult patients with type 
1 diabetes mellitus in Tunisia. Diabetes Metab 2005; 31: 83-86  
22 Ashabani A, Abushofa U, Abusrewill S, Abdelazez M, 
Tucková L, Tlaskalová-Hogenová H. The prevalence of coe-
liac disease in Libyan children with type 1 diabetes mellitus. 
Diabetes Metab Res Rev 2003; 19: 69-75 
4977 December 7, 2011|Volume 17|Issue 45|WJG|www.wjgnet.com
Greco L et al.  Celiac burden
23 Boudraa G, Hachelaf W, Benbouabdellah M, Belkadi M, 
Benmansour FZ, Touhami M. Prevalence of coeliac disease 
in diabetic children and their first- degree relatives in west 
Algeria: screening with serological markers. Acta Paediatr 
Suppl 1996; 412: 58-60
24 Shahbazkhani B, Faezi T, Akbari MR, Mohamadnejad M, 
Sotoudeh M, Rajab A, Tahaghoghi S, Malekzadeh R. Coeliac 
disease in Iranian type I diabetic patients. Dig Liver Dis 2004; 
36: 191-194
25 Byerlee D, Hesse de Polanco E. Wheat in the world food 
economy: increasing role in developing countries. Food 
Policy 1983; 8: 67-75 
26 Defra Food and Farming Group. OECD-FAO Agricultural 
outlook 2010-2019 Summary by Defra. Available from: URL: 
http://www.agri-outlook.org/
27 Wu J, Xia B, von Blomberg BM, Zhao C, Yang XW, Crusius 
JB, Peña AS. Coeliac disease: emerging in China? Gut 2010; 
59: 418-419
28 Makharia GK, Verma AK, Amarchand R, Bhatnagar S, Das 
P, Goswami A, Bhatia V, Ahuja V, Datta Gupta S, Anand 
K. Prevalence of celiac disease in the northern part of India: 
a community based study. J Gastroenterol Hepatol 2011; 26: 
894-900 
29 Long KH, Rubio-Tapia A, Wagie AE, Melton LJ, Lahr BD, 
Van Dyke CT, Murray JA. The economics of coeliac disease: 
a population-based study. Aliment Pharmacol Ther 2010; 32: 
261-269 
30 Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, 
Chinburapa V. Economic benefits of increased diagnosis of 
celiac disease in a national managed care population in the 
United States. J Insur Med 2008; 40: 218-228 
31 Hershcovici T, Leshno M, Goldin E, Shamir R, Israeli E. 
Cost effectiveness of mass screening for coeliac disease is 
determined by time-delay to diagnosis and quality of life on 
a gluten-free diet. Aliment Pharmacol Ther 2010; 31: 901-910  
32 Elsurer R, Tatar G, Simsek H, Balaban YH, Aydinli M, Sok-
mensuer C. Celiac disease in the Turkish population. Dig 
Dis Sci 2005; 50: 136-142
33 Masjedizadeh R, Hajiani E, Hashemi J, Shayesteh AA, 
Moula K, Rajabi T. Celiac disease in South-West of Iran. 
World J Gastroenterol 2006; 12: 4416-4419 
34 Fayed SB, Aref MI, Fathy HM, Abd El Dayem SM, Emara 
NA, Maklof A, Shafik A. Prevalence of celiac disease, Heli-
cobacter pylori and gastroesophageal reflux in patients with 
refractory iron deficiency anemia. J Trop Pediatr 2008; 54: 
43-53
35 Qari FA. Clinical presentation of adult celiac disease in 
Western Saudi Arabia. Saudi Med J 2002; 23: 1514-1517  
36 Doganci T, Bozkurt S. Celiac disease with various presenta-
tions. Pediatr Int 2004; 46: 693-696 
37 Kuloğlu Z, Kirsaçlioğlu CT, Kansu A, Ensari A, Girgin N. 
Celiac disease: presentation of 109 children. Yonsei Med J 
2009; 50: 617-623
38 Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, 
Vogelsang H. Prevalence and clinical importance of hy-
pertransaminasaemia in coeliac disease. Eur J Gastroenterol 
Hepatol 1999; 11: 283-288
39 Biagi F, Corazza GR. Mortality in celiac disease. Nat Rev 
Gastroenterol Hepatol 2010; 7: 158-162 
40 Rostom A, Murray JA, Kagnoff MF. American Gastroenter-
ological Association (AGA) Institute technical review on the 
diagnosis and management of celiac disease. Gastroenterol-
ogy 2006; 131: 1981-2002
41 Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in 
celiac disease. Gastroenterology 1989; 97: 265-271
42 Cottone M, Termini A, Oliva L, Magliocco A, Marrone C, 
Orlando A, Pinzone F, Di Mitri R, Rosselli M, Rizzo A, Pa-
gliaro L. Mortality and causes of death in celiac disease in a 
Mediterranean area. Dig Dis Sci 1999; 44: 2538-2541
43 Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, Cot-
tone M, Sategna Guidetti C, Usai P, Cesari P, Pelli MA, Lo-
perfido S, Volta U, Calabró A, Certo M. Mortality in patients 
with coeliac disease and their relatives: a cohort study. Lan-
cet 2001; 358: 356-361
44 Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, 
Erdtmann F, Brantner TL, Kim WR, Phelps TK, Lahr BD, 
Zinsmeister AR, Melton LJ, Murray JA. Increased preva-
lence and mortality in undiagnosed celiac disease. Gastroen-
terology 2009; 137: 88-93
45 Sanders DS, Hurlstone DP, Stokes RO, Rashid F, Milford-
Ward A, Hadjivassiliou M, Lobo AJ. Changing face of adult 
coeliac disease: experience of a single university hospital in 
South Yorkshire. Postgrad Med J 2002; 78: 31-33
46 Jones S, D’Souza C, Haboubi NY. Patterns of clinical pre-
sentation of adult coeliac disease in a rural setting. Nutr J 
2006; 5: 24
47 Abadie V, Sollid LM, Barreiro LB, Jabri B. Integration of 
genetic and immunological insights into a model of celiac 
disease pathogenesis. Annu Rev Immunol 2011; 29: 493-525
48 Cataldo F, Lio D, Simpore J, Musumeci S. Consumption of 
wheat foodstuffs not a risk for celiac disease occurrence in 
burkina faso. J Pediatr Gastroenterol Nutr 2002; 35: 233-234  
49 Fasano A. Celiac disease--how to handle a clinical chame-
leon. N Engl J Med 2003; 348: 2568-2570 
50 Martinelli P, Troncone R, Paparo F, Torre P, Trapanese E, 
Fasano C, Lamberti A, Budillon G, Nardone G, Greco L. Co-
eliac disease and unfavourable outcome of pregnancy. Gut 
2000; 46: 332-335
S- Editor  Sun H    L- Editor  Rutherford A    E- Editor  Li JY 
4978 December 7, 2011|Volume 17|Issue 45|WJG|www.wjgnet.com
Greco L et al.  Celiac burden
